EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Anastrozole vs Letrozole to Augment Height in Pubertal Males With Idiopathic Short Stature: A 3-Year Randomized Trial

Walter Zegarra, Sayali Ranadive, Diane Toulan, E Kirk Neely iD

Journal of the Endocrine Society · 27.08.2024 · 8 (10)

DOI: 10.1210/jendso/bvae141 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the Endocrine Society, online erschienen am 27.08.2024. Verfasst von Walter Zegarra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Endocrinology and Diabetes, Stanford University School of Medicine, Stanford, CA 94305-5660, USA. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Stanford Maternal and Child Health Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Insufficient efficacy and safety data for off-label use of aromatase inhibitors to augment height in boys with short stature.

Objective

To compare anastrozole and letrozole in treatment of idiopathic short stature in pubertal boys.

Design

Open-label trial with 2 treatment arms.

Setting

Pediatric Endocrine Clinic at Stanford.

Participants

A total of 79 pubertal males ≥10 years with bone age (BA) ≤ 14 years, predicted adult height (PAH) < 5th percentile or >10 cm below mid-parental height.

Intervention

Anastrozole 1.0 mg or letrozole 2.5 mg daily for up to 3 years. Main Outcome Measures Annual hormone levels and growth parameters during treatment and a year posttherapy; annual BA and PAH (primary outcome measure); spine x-rays and dual energy X-ray absorptiometry at baseline and 2 years.

Results

Compared with anastrozole (n = 35), letrozole (n = 30) resulted in higher testosterone levels, lower estradiol and IGF-1 levels, and slower growth velocity and BA advance. The PAH increase observed at year 1 in both groups did not persist at years 2 and 3. Change in PAH from baseline was not different between treatment groups. In groups combined, PAH gain over 3 years vs baseline was +1.3 cm (P = .043) in linear mixed models.

Conclusion

Letrozole caused greater deviations than anastrozole in hormone levels, growth velocity, and BA advancement, but no group differences in PAH or side effects were found. Change in PAH after 2 to 3 years of treatment was minimal. The efficacy of AI as monotherapy for height augmentation in pubertal boys with idiopathic short stature may be limited, and safety remains an issue.

Schlagwörter

Stichwörter der Autor:innen

anastrozolearomatase inhibitorheightletrozolepuberty

Autor:innen und Institutionen

  • Division of Pediatric Endocrinology and Diabetes, Stanford University School of Medicine, Stanford, CA 94305-5660, USA.
  • Pediatric Endocrinology, Palo Alto Medical Foundation, Palo Alto, CA 94301, USA.

ORCID-Profile: E Kirk Neely

Förderung

  • Stanford Maternal and Child Health Research Institute

Zitieren

APA

Zegarra, W., Ranadive, S., Toulan, D., & Neely, E. K. (2024). Anastrozole vs Letrozole to Augment Height in Pubertal Males With Idiopathic Short Stature: A 3-Year Randomized Trial. Journal of the Endocrine Society, 8(10). https://doi.org/10.1210/jendso/bvae141

Vancouver

Zegarra W, Ranadive S, Toulan D, Neely EK. Anastrozole vs Letrozole to Augment Height in Pubertal Males With Idiopathic Short Stature: A 3-Year Randomized Trial. Journal of the Endocrine Society. 2024;8(10). doi:10.1210/jendso/bvae141

BibTeX
@article{Zegarra2024,
  author = {Zegarra, Walter and Ranadive, Sayali and Toulan, Diane and Neely, E Kirk},
  title = {Anastrozole vs Letrozole to Augment Height in Pubertal Males With Idiopathic Short Stature: A 3-Year Randomized Trial},
  journal = {Journal of the Endocrine Society},
  year = {2024},
  volume = {8},
  number = {10},
  doi = {10.1210/jendso/bvae141}
}
Kostenlos starten →